Allogene Therapeutics
ALLO
94 hedge funds and large institutions have $1.85B invested in Allogene Therapeutics in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
26% more call options, than puts
Call options by funds: $2.94M | Put options by funds: $2.34M
9% more funds holding
Funds holding: 86 → 94 (+8)
2.85% more ownership
Funds ownership: 53.83% → 56.67% (+2.8%)
2% less capital invested
Capital invested by funds: $1.88B → $1.85B (-$33.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$53.6M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$53.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.4M |
| 4 |
BlackRock
New York
|
+$36.6M |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$27.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$53.5M |
| 2 |
VM
VV Manager
Boston,
Massachusetts
|
-$50.1M |
| 3 |
Jennison Associates
New York
|
-$24M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$10.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RJA
101
Raymond James & Associates
St Petersburg,
Florida
| – | -$1.21M | -42,000 | Closed |
|
102
Arrowstreet Capital
Boston,
Massachusetts
| – | -$824K | -28,500 | Closed |
|
|
SO
103
STRS Ohio
Columbus,
Ohio
| – | -$167K | -5,800 | Closed |
|
|
FAM
104
Fred Alger Management
New York
| – | -$145K | -5,000 | Closed |
|
|
CCA
105
Catalyst Capital Advisors
Huntington,
New York
| – | -$5K | -179 | Closed |
|
106
Bessemer Group
Woodbridge,
New Jersey
| – | -$4K | -130 | Closed |
|
ALLO Hedge Fund Activity: Q2 2019 in Review
94 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2019, worth a combined $1.85B — down 1.8% from $1.88B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ALLO positions and 13 closed out — a net gain of 12 holders — while 38 added to existing stakes and 20 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $53.6M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $53.5M.
- 94 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2019, up from 86 in Q1 2019.
- Funds reported $1.85B of Allogene Therapeutics stock for Q2 2019, down 1.8% quarter-over-quarter.
- 25 funds opened new Allogene Therapeutics positions in Q2 2019 and 13 closed out, a net change of +12 holders.
- The largest Allogene Therapeutics buyer in Q2 2019 was Capital Research Global Investors, an estimated $53.6M added.
- The largest Allogene Therapeutics seller in Q2 2019 was TPG Group Holdings (SBS) Advisors, an estimated $53.5M sold.
Based on aggregated 13F filings for Q2 2019.